The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Nikonova T.V.

Éndokrinologicheskiĭ nauchnyĭ tsentr RAMN, Moskva

NPH insulin. Effective mixing - effective dose regimen

Authors:

Nikonova T.V.

More about the authors

Journal: Problems of Endocrinology. 2011;57(4): 56‑60

Read: 1666 times


To cite this article:

Nikonova TV. NPH insulin. Effective mixing - effective dose regimen. Problems of Endocrinology. 2011;57(4):56‑60. (In Russ.)

References:

  1. Brostoff J.M., Keen N., Brostoff J. A diabetic life before and after insulin era. Diabetologia 2007; 50: 1351-1353.
  2. Alberti G. Lessons from the history of insulin. Diabetes Voice 2001; 46: 33-34.
  3. Ozawa H., Murai Y., Ozawa T. A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus. Yakushigaku Zasshi 2003; 38: 1-27.
  4. Laubach E., Schwandt P., Ritter M.M. Neutral protamine Hagedorn insulin. Lancet 2000; 355: 236.
  5. Murnaghan J.H., Talalay P. John Jacob Abel and the crystallization of insulin. Persp Biol Med 1967; 10: 334-381.
  6. Balabolkin M.I., Klebanova E.M., Kreminskaya B.M. Lechenie sakharnogo diabeta i ego oslozhnenii. Meditsina 2005; 512.
  7. Heinemann L., Sinha K., Weyer S. et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999; 16: 332-338.
  8. Scholtz H.E., Pretorius S.G., Wessels D.H., Becker R.H. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using an euglycaemic clamp technique. Diabetologia 2005; 48: 1988-1995.
  9. American Diabetes Association. Clinical practice recommendations. Diabetes Care 2009; 32: Suppl l: l-98.
  10. Bantle J.P., Neal L., Frankamp L.M. Effects of the anatomical region used for insulin injections on glycemia in type 1 diabetes subjects. Diabetes Care 1993; 16: 1592-1597.
  11. Thow J.C., Johnson A.B., Fulcher G., Home P.D. Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Diabet Med 1990; 7: 600-602.
  12. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002; 4: 673-682.
  13. Hänel H., Weise A., Sun W. et al. Differences in the dose accuracy of insulin pens. J Diabetes Sci Technol 2008; 2: 478-481.
  14. Jorgensen J.O., Flyvbjerg A., Jorgensen J.T. et al. NPH insulin administration by means of a pen injector. Diabet Med 1998; 55: 574-576.
  15. Fisken R.A., Goulbourn J. Treatment of insulin-dependent diabetes using an injection pen: control, problems and patients preferences. Diabetes Res 1989; 11: 195-197.
  16. Jehle P.M., Micheler C., Jehle D.R. et al. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet 1999; 354: 1604-1607.
  17. Brown A., Steel J.M., Duncan S. et al. An assessment of the adequacy of suspension of insulin in pen injectors. Diabet Med 2004; 21: 604-608.
  18. Kaiser P., Maxeiner S., Weise A. et al. Assessment of the Mixing Efficiency of Neutral Protamine Hagedorn Cartridges. J Diabetes Sci Technol 2010; 4: 652-657.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.